Valeant Pharmaceuticals International, Inc. s in-depth stock price analysis indicates that the stock price has dropped -16.21% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -51.22% . Looking at the past 52 week period, the stock price is down -82.99% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Valeant Pharmaceuticals International, Inc. has a negative value of -44.79 compared to overall market performance. Stocks of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) rallied by 5.77% during the past week but lost 1.89% on a 4-week basis. The company has outperformed the S&P 500 by 4.91% in the past week but underperformed the index by 3.65% in the last 4 weeks.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) : On Friday heightened volatility was witnessed in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) which led to swings in the share price. The stock opened for trading at $14.96 and hit $15.24 on the upside , eventually ending the session at $15.04, with a gain of 0.8% or 0.12 points. The heightened volatility saw the trading volume jump to 8,468,670 shares. The 52-week high of the share price is $96.62 and the company has a market cap of $5,229 million. The 52-week low of the share price is at $13 .
Valeant Pharmaceuticals Intl Inc Last issued its quarterly earnings results on Nov 8, 2016. The company reported $1.55 EPS for the quarter, missing the analyst consensus estimate by $ -0.21. Analyst had a consensus of $1.76. The company had revenue of $2479.60 million for the quarter, compared to analysts expectations of $2508.67 million. The companys revenue was down -11.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $2.41 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Valeant Pharmaceuticals Intl Inc was Reiterated by Barclays on Feb 10, 2017 to Equal Weight, Lowers Price Target to $ 20 from a previous price target of $34 .Valeant Pharmaceuticals Intl Inc was Reiterated by Piper Jaffray on Jan 4, 2017 to Underweight, Lowers Price Target to $ 11 from a previous price target of $16 .Valeant Pharmaceuticals Intl Inc was Downgraded by Morgan Stanley on Dec 15, 2016 to Equal-Weight, Lowers Price Target to $ 17 from a previous price target of $25 .Valeant Pharmaceuticals Intl Inc was Downgraded by Mizuho on Nov 23, 2016 to Underperform, Lowers Price Target to $ 11 from a previous price target of $25 .Valeant Pharmaceuticals Intl Inc was Reiterated by Deutsche Bank on Nov 14, 2016 to Hold, Lowers Price Target to $ 24 from a previous price target of $29 .
Company has reported several Insider transactions to the SEC, on Dec 16, 2016, Thomas W. Sr. Ross (director) purchased 5,000 shares at 14.73 per share price.On Aug 12, 2016, Argeris N Karabelas (director) purchased 4,000 shares at 24.65 per share price.On Jun 13, 2016, Joseph C Papa (CEO) purchased 202,000 shares at 24.48 per share price.
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeants development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.